This British mid-cap is a successful global player with plenty of room for expansion, says Dr Mike Tubbs.
Articles written by Dr Mike Tubbs
Immunotherapy is a burgeoning sector that heralds a breakthrough against the world’s second-most deadly disease. Dr Mike Tubbs explains how investors can benefit too.
Alexion focuses on diseases that affect only a tiny proportion of the population – a lucrative niche.
Illumina, the genome sequencing specialist, is a leader in a thriving market. Long-term investors should buy now, says Mike Tubbs.
Companies that spend heavily on research and development (R&D) greatly improve their long-term odds. Dr Mike Tubbs explains what to look out for – and what to buy now.
Companies with a consistent record of rising payouts look especially attractive at present. Dr Mike Tubbs introduces his favourite “dividend aristocrats”.
Few people have heard of Renishaw, but its products and prospects are excellent, says Mike Tubbs.
Salesforce, one of the world’s top software companies, has a bright future and is currently on sale.
Shares in German biotech MorphoSys firm could double as the royalties start to roll in, says Mike Tubbs.
You might not think of the UK as a market full of promising tech stocks. But our small- and medium-sized companies are punching above their weight, says Dr Mike Tubbs.